Lansoprazole Tablet, Orally Disintegrating, Delayed Release
Product Images NDC 72603-313

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 72603-313). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Lansoprazole Fig1)

A line graph titled "Mean Severity of Day Heartburn By Study Day For Evaluable Patients" displaying mean heartburn severity (scale 0 to 3) versus days from start of treatment (-5 to 60). It compares three groups: Placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD, showing severity decreasing more rapidly for both Lansoprazole doses compared to placebo over time.*

FDA Label Image

Figure2 (Lansoprazole Fig2)

A line graph titled 'Mean Severity of Night Heartburn By Study Day For Evaluable Patients,' showing mean severity scores (0-3 scale) over days from treatment start. It compares three groups: placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD, illustrating decreasing heartburn severity over approximately 60 days for the Lansoprazole groups versus placebo.*

FDA Label Image

Figure (Lansoprazole Fig3)

Packaging label for Lansoprazole Delayed-Release Orally Disintegrating Tablets 15 mg by NorthStar Rx LLC. The label indicates 100 unit-dose tablets (10 x 10) and includes instructions for pharmacists and patients. The label features a blue and white design with the product name and strength prominently displayed.*

FDA Label Image

Figure (Lansoprazole Fig4)

Packaging label for Lansoprazole Delayed-Release Orally Disintegrating Tablets, 30 mg strength. The label features the NorthStar Rx LLC logo and states a package size of 100 unit-dose tablets (10 x 10). Instructions for pharmacist dispensing and patient use are visible, along with storage conditions and manufacturer details: Aurobindo Pharma Limited, India. The design includes blue and white colors with a depiction of a speckled tablet.*

FDA Label Image

Chemical Structure (Lansoprazole Str)

Chemical structure of Lansoprazole, showing the molecular arrangement of its atoms, including a benzimidazole ring, sulfoxide group, and substituted pyridine moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.